Trevi Therapeutics (NASDAQ:TRVI) Announces Quarterly Earnings Results

Trevi Therapeutics (NASDAQ:TRVI) announced its earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01, Zacks reports.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $6.56 on Wednesday. The stock has a market cap of $504.24 million, a P/E ratio of -14.91 and a beta of 0.90. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.39. The firm’s fifty day moving average price is $4.44 and its 200-day moving average price is $3.68.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 24.37% of the company’s stock.

Analyst Upgrades and Downgrades

TRVI has been the topic of several recent research reports. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. D. Boral Capital reissued a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Friday, March 7th. Needham & Company LLC boosted their target price on Trevi Therapeutics from $8.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Oppenheimer upped their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Finally, HC Wainwright upped their price objective on Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a research note on Monday, March 10th. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $15.94.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.